二零二五年十一月 目 录 天津金诺律师事务所 关于天津力生制药股份有限公司 2022 年股权激励计划预留授予部分第一个 解除限售期条件成就事项 之 法律意见书 | 一、本次股权激励计划相关事项的批准和授权 | 3 | | --- | --- | | 二、关于本次解除限售条件成就的具体情况 | 5 | | 三、结论意见 | 8 | 天津市区：中国·天津和平区徐州道 122 号万通中心 23 层 邮编 300042 滨海新区：中国·天津市滨海新区新城西路 5 号周大福金融中心 2204-2205 邮编 300450 天津金诺律师事务所 关于天津力生制药股份有限公司 2022 年股权激励计划预留授予部分 第一个解除限售期条件成就事项之 法律意见书 致：天津力生制药股份有限公司 天津金诺律师事务所（以下简称"本所"）接受天津力生制药股份有限公司 （以下简称"公司"或"力生制药"）的委托，担任公司 2022 年限制性股票激 励计划（以下简称"本次激励计划"或"本激励计划"）的法律顾问。本所根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司股权激励管 ...

Market Overview - On November 12, the Tianjin state-owned enterprise reform sector declined by 0.36% compared to the previous trading day, with Baili Electric leading the decline [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Key stocks in the Tianjin state-owned enterprise reform sector showed mixed performance, with T-712 rising by 1.98% to close at 20.56, and Baili Electric falling by 3.54% to close at 7.08 [1][2] - The trading volume and turnover for T-712 were 302,000 shares and 636 million yuan, respectively [1] Capital Flow - The Tianjin state-owned enterprise reform sector experienced a net outflow of 102 million yuan from institutional investors, while retail investors saw a net inflow of 168 million yuan [2] - The capital flow data indicates that while institutional and speculative funds withdrew, retail investors were actively buying into the sector [2][3] Individual Stock Analysis - T-712 had a net inflow of 78.32 million yuan from institutional investors, while Baili Electric saw a significant outflow of 78.51 million yuan [3] - The stock of Tianjin Port closed at 4.89, down 0.41%, with a trading volume of 209,600 shares [2][3]

Group 1 - The core viewpoint of the news is that Lisheng Pharmaceutical experienced a slight decline in stock price and notable changes in financing activities on November 11, with a net financing outflow of 856.65 million yuan [1] - On November 11, Lisheng Pharmaceutical had a trading volume of 78.11 million yuan, with a financing buy-in amount of 14.07 million yuan and a financing repayment of 22.64 million yuan [1] - As of November 11, the total balance of margin trading for Lisheng Pharmaceutical was 234 million yuan, which accounts for 4.27% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of October 20, the number of shareholders for Lisheng Pharmaceutical was 23,900, reflecting a slight increase of 0.13%, while the average circulating shares per person decreased by 0.13% to 10,479 shares [2] - For the period from January to September 2025, Lisheng Pharmaceutical reported an operating income of 1.007 billion yuan, a year-on-year decrease of 1.61%, while the net profit attributable to shareholders increased by 119.05% to 371 million yuan [2] Group 3 - Since its A-share listing, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed over the past three years [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 截至2025年11月11日，公司间接控股股东天津泰达投资控股（集团）有限公司持有渤海银行股份有限公 司20.34%的股权，为渤海银行股份有限公司第一大股东，根据《深圳证券交易所股票上市规则》第 6.3.3条的相关规定，渤海银行股份有限公司为公司的关联方，公司与渤海银行股份有限公司发生的交 易，构成公司的关联交易。 二、关联方基本情况 公司名称：渤海银行股份有限公司 法定代表人：王锦虹 住所：天津市河东区海河东路218号渤海银行大厦 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第五十次会议、 2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用闲置自有资金进行现金管理 额度的议案》《关于公司2025年度现金管理暨关联交易额度的议案》，同意公司使用额度不超过人民币 10亿元闲置自有资金购买安全性高、流动性好、主要由大型商业银行或证券机构发行的短期理财产品， 包括但不限于通过银行、证券等专业理财机构购买的 ...

Group 1 - The company Tianjin Development (00882.HK) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceuticals [1] - The agreement is with Bohai Bank for a structured deposit with a principal amount of RMB 210 million, equivalent to approximately HKD 230 million [1]

Group 1 - The company Tianjin Development (00882) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393) [1] - Lifesun Pharmaceutical entered into a structured deposit agreement with Bohai Bank, with a principal amount of RMB 210 million [1]

Group 1 - The company Tianjin Development (00882) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lisheng Pharmaceutical, with Bohai Bank [1] - The agreement includes a structured deposit with a principal amount of RMB 210 million [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-069 天津力生制药股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次进行现金管理购买理财产品情况 公司以自有资金共计21,000万元人民币在渤海银行股份有限公司天津长江道支行（以 下简称"渤海银行"）购买理财产品。具体情况如下： | 产品： | 结构性存款 | | --- | --- | | 产品类型： | 保本浮动收益型 | | 风险等级： | R1（低风险） | | 产品期限： | 天 365 | | 认购金额（万元）： | 21,000 | | 产品购买时间： | 2025 年 11 月 11 日 | 1 预期收益率（年化）： 1.2% -2.0%（具体以实际到期收益率为准） 截至2025年11月11日，公司间接控股股东天津泰达投资控股（集团）有限公司持有渤 海银行股份有限公司20.34%的股权，为渤海银行股份有限公司第一大股东，根据《深圳证 券交易所股票上市规则》第6.3.3条的相关规定，渤海银行股份有限公司为公司的关联方， ...

Core Viewpoint - The company, Lifesun Pharmaceutical (002393), is focusing on balancing shareholder returns with business development, emphasizing the importance of sharing growth benefits with investors [2]. Group 1: Stock Performance - As of November 7, 2025, Lifesun Pharmaceutical's stock closed at 21.67 yuan, with a slight increase of 0.28% [1]. - The trading volume was 24,800 shares, resulting in a transaction amount of 53.79 million yuan [1]. Group 2: Investor Relations - An investor expressed concerns regarding the company's dividend policy, suggesting that the company should distribute more dividends to attract long-term investors like social security funds and insurance capital [2]. - The company’s secretary acknowledged the investor's feedback, stating that the current dividend policy aims to balance business growth and shareholder returns, taking into account industry characteristics, profitability, and cash flow [2]. Group 3: Market Sentiment - On November 7, there was a net outflow of 1.58 million yuan from institutional investors, while retail investors saw a net inflow of 2.78 million yuan, indicating a divergence in short-term trading sentiment [3]. - Retail investors experienced a net outflow of 1.20 million yuan on the same day [3].

Core Viewpoint - The Tianjin state-owned enterprise reform sector experienced a slight decline of 0.13% on November 4, with Lisheng Pharmaceutical leading the losses. The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1][2]. Stock Performance Summary - The following stocks in the Tianjin state-owned enterprise reform sector showed varying performance: - Tianjin Bin Development (Code: 000897) closed at 2.39, up 1.70% with a trading volume of 581,600 shares and a turnover of 139 million yuan [1]. - Tianjin Investment City Development (Code: 600322) closed at 2.61, up 1.56% with a trading volume of 359,200 shares and a turnover of 93.08 million yuan [1]. - Lisheng Pharmaceutical (Code: 002393) closed at 21.39, down 1.66% with a trading volume of 33,000 shares and a turnover of 70.82 million yuan [2]. - Bohai Chemical (Code: 600800) closed at 4.08, down 0.24% with a trading volume of 228,500 shares and a turnover of 93.09 million yuan [2]. Capital Flow Analysis - On the same day, the Tianjin state-owned enterprise reform sector saw a net outflow of 114 million yuan from institutional investors, while retail investors contributed a net inflow of 138 million yuan [2][3]. - The capital flow for specific stocks indicated: - Lisheng Pharmaceutical experienced a significant net outflow of 11.29 million yuan from institutional investors, with a retail net inflow of 7.32 million yuan [3]. - Tianjin Port (Code: 600717) had a net outflow of 11.99 million yuan from institutional investors, while retail investors contributed a net inflow of 10.89 million yuan [3].